| Literature DB >> 31247036 |
Joram Luke Sunguti1, Appolinaire Tiam2, Rose Masaba1, Michael Waweru1, Judith Kose2, Justine Odionyi1, Lucy Matu1, Eliud Mwangi1.
Abstract
BACKGROUND: People living with HIV (PLHIV) often face barriers in accessing quality and comprehensive HIV care, including stigma and discrimination, which results in poor retention and viral non-suppression. Peer-led interventions can help address these barriers. In Kenya, peer educators (PEs) are PLHIV who support other PLHIV to adhere to clinic schedules and antiretroviral medication uptake. In spite of their status as role models and their key role in supporting clients receiving HIV care and treatment, little is known about the characteristics and treatment outcomes of PEs themselves, specifically viral suppression.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31247036 PMCID: PMC6597086 DOI: 10.1371/journal.pone.0218774
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Roles and responsibilities of PEs (adapted from the Kenya task shifting guidelines).
| Management of patient appointment |
| • Updating of the appointment card and diary |
| Defaulter tracing and management |
| • Compilation of daily missed appointments |
| Adherence counselling |
| • Conducting psychosocial assessment |
| Psychosocial support |
| • Establishment of psychosocial support groups (PSSG) and ensuring that they are functional |
| Referral and linkages |
| • Referral of clients to service points within the facility |
| Record keeping |
| • Filing of patient records |
Fig 1Participant enrollment into the study.
Sex-specific characteristics of 230 HIV-positive PEs in 140 sites in Kenya.
| Characteristics | N (Column %) or Median (LQ, UQ)) | P value* | ||
|---|---|---|---|---|
| Total | Male | Female | ||
| Marital status | ||||
| Married | 144 (63%) | 53 (93%) | 91 (52%) | |
| Divorced | 8 (3%) | 1 (2%) | 7 (4%) | 0.27 |
| Single | 9 (4%) | 3 (5%) | 6 (4%) | 0.75 |
| Widow/Widower | 69 (30%) | 0 (0%) | 69 (40%) | |
| Median age in years (LQ, UQ) | 38.5 (33.0, 42.0)) | 42.0 (36.0, 48.0) | 37.0 (32.0, 42.0)) | |
| Median duration on ART in months (LQ, UQ) | 76.0 (37.0, 105.0) | 76.0 (49.5, 104.0)) | 76.0 (35.5, 105.0) | 0.38 |
| WHO staging at enrollment | ||||
| Stage 1 | 71 (31%) | 15 (26%) | 56 (32%) | 0.39 |
| Stage 2 | 73 (32%) | 14 (25%) | 59 (34%) | 0.21 |
| Stage 3 | 78 (34%) | 26 (46%) | 52 (30%) | |
| Stage 4 | 8 (3%) | 2 (3%) | 6 (4%) | 0.18 |
| Mean CD4 in cells/mm3 (SD) | 350 (260) | 321 (254) | 359 (4) | 0.33 |
| CD4 category | ||||
| <200 | 61 (27%) | 19 (33%) | 42 (24%) | 0.18 |
| 200+ | 169 (73%) | 38 (67%) | 131 (76%) | 0.18 |
| Current ART regimen | ||||
| TDF/3TC/EFV | 102 (44%) | 23 (40%) | 79 (46%) | 0.43 |
| AZT/3TC/NVP | 75 (33%) | 20 (35%) | 55 (32%) | 0.68 |
| TDF/3TC/NVP | 30 (13%) | 9 (16%) | 21 (12%) | 0.43 |
| AZT/3TC/EFV | 12 (5%) | 4 (7%) | 8 (5%) | 0.57 |
| Other | 11 (5%) | 1 (2%) | 10 (5%) | 0.33 |
| Completed 6 months of IPT | ||||
| Yes | 219 (95%) | 55 (96%) | 164 (95%) | 0.76 |
| No | 11 (5%) | 2 (4%) | 9 (5%) | 0.76 |
| Viral load taken within the last 12 months | ||||
| Yes | 222 (97%) | 54 (95%) | 168 (97%) | 0.48 |
| No | 8 (3%) | 3 (5%) | 5 (3%) | 0.48 |
| Virally suppressed (VL < 1000 copies/ml) | ||||
| Yes | 211 (95%) | 48 (89%) | 163 (97) | |
| No | 11 (5%) | 6 (11%) | 5 (3%) | 0.4 |
Univariate correlates of viral suppression among 222 HIV-positive PEs in 140 sites in Kenya.
| Characteristic | Viral suppression: N (Row %) | ||
|---|---|---|---|
| Suppressed | Unsuppressed | RR for unsuppression (95% CI) | |
| Sex | |||
| Male (Ref) | 48 (89%) | 6 (11%) | - |
| Female | 163 (97%) | 5 (3%) | 0.9 (0.8–1.0) |
| Marital status | |||
| Married (Ref) | 128 (93%) | 9 (7%) | - |
| Not married | 83 (98%) | 2 (2%) | 0.9 (0.9–1.0) |
| Age (years) | |||
| <30 | 23 (82%) | 5 (18%) | - |
| 30–39 | 92 (98%) | 2 (2%) | 0.8 (0.7–1.0) |
| 40–49 | 79 (98%) | 2 (2%) | 0.8 (0.7–1.0) |
| 50+ | 17 (89%) | 2 (11%) | 0.9 (0.7–1.2) |
| Duration on ART (months) | |||
| <36 | 44 (96%) | 2 (4%) | - |
| 36–71 | 55 (96%) | 2 (4%) | 1.0 (0.9–1.1) |
| 72+ | 112 (94%) | 7 (6%) | 1.0 (0.9–1.1) |
| WHO staging at enrollment | |||
| Non-advanced disease (WHO stage 1 and 2) (Ref) | 132 (96%) | 6 (4%) | - |
| Advanced disease (WHO stage 3 and 4) | 79 (94%) | 5 (6%) | 1.0 (0.9–1.1) |
| Baseline CD4 (cells/mm3) | |||
| <200 | 53 (90%) | 6 (10%) | - |
| 200+ | 158 (97%) | 5 (3%) | 0.9 (0.8–1.0) |
| Current ART regimen (Backbone) | |||
| TDF based (Ref) | 122 (95%) | 6 (5%) | - |
| AZT based | 82 (96%) | 3 (4%) | 0.9 (0.9–1.0) |
| Current ART regimen (Tail) | |||
| EFV-based (Ref) | 105 (96%) | 4 (4%) | - |
| NVP-based | 99 (95%) | 5 (5%) | 1.0 (0.9–1.1) |
| Received IPT | |||
| Yes | 202 (95%) | 11 (5%) | - |
| No | 9 (100%) | 0 (0%) | - |
*Includes single, divorced and widow/widower